Adagio Medical Holdings, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) develops and commercializes innovative ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company offers a portfolio of ultra-low temperature cryoablation (ULTC) and pulsed field cryoablation (PFCA) systems; iCLAS atrial ULTC catheter and accessories for paroxysmal atrial fibrillation, persistent atrial fibrillation, and atrial flutter, with CE mark in the European Union; vCLAS ventricular ULTC catheter designed for ventricular arrhythmias; Cryopulse atrial PFCA catheter and accessories; and a shared ULTC cryoablation console across its catheter families. Founded in 2011 and headquartered in Laguna Hills, California, Adagio Medical Holdings operates primarily in the United States and European Union markets, targeting electrophysiologists and healthcare providers treating patients with drug-resistant arrhythmias. In July 2024, the company completed a business combination with ARYA Sciences Acquisition Corp IV, listing on Nasdaq under the ADGM ticker and raising approximately $84.2 million in financing from investors including affiliates of Perceptive Advisors, RA Capital Management, RTW Investments, and ATW Partners. In October 2025, Adagio Medical Holdings closed a private placement providing up to $50 million in gross proceeds, including $19 million upfront led by Perceptive Advisors and other healthcare-focused investors, to fund FDA submission for the vCLAS ULTC System via the FULCRUM-VT pivotal study, next-generation catheter development, manufacturing expansion, and commercial readiness. The company completed enrollment in the 209-patient FULCRUM-VT US IDE trial in third quarter 2025, reporting 97% acute effectiveness and a favorable safety profile, alongside securing FDA Breakthrough Device Designation, CMS Category B coverage, and leadership additions including Deborah Kaster as Chief Financial Officer.
Adagio Medical Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation System for the Treatment of Ventricular Tachycardia
Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress
Adagio Medical to Participate in the BofA Securities 2026 Health Care Conference
Adagio Medical Announces Positive Pivotal Results for vCLAS® Ventricular Ablation System
Adagio Medical Holdings, Inc. (NASDAQ:ADGM) Sees Large Growth in Short Interest
Sensus Healthcare (NASDAQ:SRTS) versus Adagio Medical (NASDAQ:ADGM) Head to Head Contrast
Adagio Medical's ULTA Technology to Be Featured at the Heart Rhythm 2026 Conference
Short Interest in Adagio Medical Holdings, Inc. (NASDAQ:ADGM) Rises By 60.0%
Adagio Medical Receives IDE Approval from the FDA to Investigate Next-Generation vCLAS® Ventricular Ablation System
Adagio Medical to Participate in the 25th Annual Needham Virtual Conference
Adagio Medical Ultralow Temperature Ablation U.S. Pivotal Study Results to be Presented in Late-Breaking Session at Heart Rhythm Society 2026
Adagio Medical Reports Fourth Quarter and Full Year 2025 Results
Adagio Medical Announces Publication of Pre-Clinical Results for Next Generation Ventricular Ablation Catheter
Adagio Medical Highlights Recent Successful Expanded Access Cases with vCLAS™ System, Including Patients with Premature Ventricular Contractions (PVC)
Adagio Medical to Participate in the 38th Annual Roth Conference
Adagio Medical Holdings, Inc. (NASDAQ:ADGM) Short Interest Up 31.5% in February
Adagio Medical to Participate in the TD Cowen 46th Annual Healthcare Conference
New Adagio Medical Publication Highlights Consistent Safety and Effectiveness with Ultralow Temperature Ablation in Broad Range of Patients with Ventricular Tachycardia
Adagio Medical to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Adagio Medical to Present at the Small Cap Growth Virtual Investor Conference February 5th